相似文献
1
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.
Cancer Cell. 2009 Jun 2;15(6):539-50. doi: 10.1016/j.ccr.2009.03.027.
2
Mammary tumorigenesis through LPA receptor signaling.
Cancer Cell. 2009 Jun 2;15(6):457-9. doi: 10.1016/j.ccr.2009.05.003.
3
ATX-LPA receptor axis in inflammation and cancer.
Cell Cycle. 2009 Nov 15;8(22):3695-701. doi: 10.4161/cc.8.22.9937. Epub 2009 Nov 27.
4
Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
Br J Cancer. 2010 Mar 16;102(6):941-6. doi: 10.1038/sj.bjc.6605588.
5
Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Mol Cancer. 2011 Feb 12;10:18. doi: 10.1186/1476-4598-10-18.
6
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Mol Cancer Res. 2010 Mar;8(3):309-21. doi: 10.1158/1541-7786.MCR-09-0288. Epub 2010 Mar 2.
7
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
Mol Cell Biol. 2006 Jul;26(13):5015-22. doi: 10.1128/MCB.02419-05.
8
Requirement of Osteopontin in the migration and protection against Taxol-induced apoptosis via the ATX-LPA axis in SGC7901 cells.
BMC Cell Biol. 2011 Mar 16;12:11. doi: 10.1186/1471-2121-12-11.
9
Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Neuroscience. 2008 Mar 18;152(2):296-8. doi: 10.1016/j.neuroscience.2007.12.041. Epub 2008 Jan 9.
10
ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721.
Anat Rec (Hoboken). 2011 Mar;294(3):406-11. doi: 10.1002/ar.21324. Epub 2010 Dec 31.
引用本文的文献
1
Epitranscriptomic mechanisms and implications of RNA mC modification in cancer.
Theranostics. 2025 Jul 25;15(16):8404-8428. doi: 10.7150/thno.112332. eCollection 2025.
2
Impact of tumor necrosis factor-alpha and lysophosphatidic acid on the behavior of ovarian cancer cells in a three-dimensional collagen hydrogel.
J Obstet Gynaecol Res. 2025 Aug;51(8):e70026. doi: 10.1111/jog.70026.
3
Inhibition of autotaxin activity with IOA-289 decreases fibrosis in mouse E0771 breast tumors.
Int J Cancer. 2025 Sep 15;157(6):1205-1217. doi: 10.1002/ijc.35471. Epub 2025 May 9.
4
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.
Front Oncol. 2025 Jan 14;14:1514120. doi: 10.3389/fonc.2024.1514120. eCollection 2024.
5
Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy.
Int J Mol Sci. 2025 Jan 12;26(2):597. doi: 10.3390/ijms26020597.
6
Transcriptomic response of overexpression ZNF32 in breast cancer cells.
Sci Rep. 2024 Nov 18;14(1):28407. doi: 10.1038/s41598-024-80125-7.
7
Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study.
Molecules. 2024 Sep 10;29(18):4285. doi: 10.3390/molecules29184285.
8
Insights into autotaxin- and lysophosphatidate-mediated signaling in the pancreatic ductal adenocarcinoma tumor microenvironment: a survey of pathway gene expression.
Am J Cancer Res. 2024 Aug 25;14(8):4004-4027. doi: 10.62347/KQNW1871. eCollection 2024.
9
Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.
Int J Mol Sci. 2024 Jul 15;25(14):7737. doi: 10.3390/ijms25147737.
10
Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer.
Cell Death Discov. 2024 Mar 15;10(1):143. doi: 10.1038/s41420-024-01895-7.
本文引用的文献
1
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.
J Biol Chem. 2009 Mar 13;284(11):7385-94. doi: 10.1074/jbc.M807820200. Epub 2009 Jan 12.
2
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. doi: 10.1093/jnci/djn378. Epub 2008 Nov 11.
3
In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation.
Oncogene. 2008 Nov 20;27(54):6806-16. doi: 10.1038/onc.2008.294. Epub 2008 Sep 1.
4
Stromal gene expression predicts clinical outcome in breast cancer.
Nat Med. 2008 May;14(5):518-27. doi: 10.1038/nm1764. Epub 2008 Apr 27.
5
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
J Biol Chem. 2008 Jun 13;283(24):16818-29. doi: 10.1074/jbc.M710177200. Epub 2008 Apr 11.
6
Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts.
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5248-53. doi: 10.1073/pnas.0704242105. Epub 2008 Mar 26.
7
Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
Cancer Res. 2007 Dec 15;67(24):11751-9. doi: 10.1158/0008-5472.CAN-07-3175.
8
Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells.
Mol Cancer Res. 2007 Nov;5(11):1201-11. doi: 10.1158/1541-7786.MCR-06-0338.
9
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030.
10
Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression.
Expert Rev Mol Med. 2007 Oct 15;9(28):1-18. doi: 10.1017/S1462399407000476.
Zotero 插件